Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: Comment on the Article by Buckley et al.

Arthritis care & research·2017
Same author

Use of DXA-based technology for detection and assessment of risk of vertebral fracture in rheumatology practice.

Current rheumatology reports·2014
Same author

Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.

The Journal of bone and joint surgery. American volume·2014
Same author

Osteoporosis update from the 2010 santa fe bone symposium.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry·2011
Same author

The role of zoledronic acid in the management of osteoporosis.

Clinical rheumatology·2010
Same author

Intravenous zoledronic acid: what are the indications for male osteoporosis?

Current osteoporosis reports·2010

Related Experiment Video

Updated: May 28, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
05:55

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Update on glucocorticoid-induced osteoporosis.

Michael Maricic1

  • 1Department of Medicine, University of Arizona School of Medicine, 1501 North Campbell, Tucson, AZ 85724, USA. mikemaricic@msn.com

Rheumatic Diseases Clinics of North America
|October 26, 2011
PubMed
Summary

Glucocorticoid-induced osteoporosis (GIOP) is a common secondary osteoporosis. While effective treatments and guidelines exist, many patients still lack adequate prevention and therapy for this condition.

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Glucocorticoid-induced osteoporosis (GIOP) is the most prevalent secondary osteoporosis.
  • Fractures are a common adverse effect of glucocorticoid therapy.
  • Glucocorticoids negatively impact bone health by reducing osteoblast and osteocyte function and lifespan.

Purpose of the Study:

  • To review recent advances in understanding and managing GIOP.
  • To highlight the availability of effective pharmacologic agents and published guidelines.
  • To address the gap in patient prevention and treatment for GIOP.

Main Methods:

  • Literature review of recent advances in GIOP pathophysiology.
  • Analysis of current pharmacologic treatments for GIOP.

Related Experiment Videos

Last Updated: May 28, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
05:55

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

  • Examination of published clinical guidelines for GIOP prevention and treatment.

    • Main Results:

    • Significant progress has been made in understanding GIOP.
    • Multiple effective pharmacologic agents are available for GIOP management.
    • Established guidelines exist for the prevention and treatment of GIOP.

    Conclusions:

    • Despite advances, optimal prevention and therapy for GIOP are not universally implemented.
    • Further efforts are needed to ensure patients receive appropriate care for GIOP.
    • Improved patient outcomes are possible with adherence to guidelines and available treatments.